GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Forward PE Ratio

Sandoz Group AG (Sandoz Group AG) Forward PE Ratio : 11.64 (As of May. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Forward PE Ratio?

Sandoz Group AG's Forward PE Ratio for today is 11.64.

Sandoz Group AG's PE Ratio without NRI for today is 193.75.

Sandoz Group AG's PE Ratio for today is 208.65.


Sandoz Group AG Forward PE Ratio Historical Data

The historical data trend for Sandoz Group AG's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Forward PE Ratio Chart

Sandoz Group AG Annual Data
Trend 2023-12 2024-05
Forward PE Ratio
12.14 12.67

Sandoz Group AG Quarterly Data
2023-12 2024-03
Forward PE Ratio 12.14 10.81

Competitive Comparison of Sandoz Group AG's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Forward PE Ratio falls into.



Sandoz Group AG Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sandoz Group AG  (OTCPK:SDZNY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sandoz Group AG Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG (Sandoz Group AG) Business Description

Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024